Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.

3058 Background: AZD7762, a potent Chk1/Chk2 inhibitor, has shown chemosensitizing activity with gem in preclinical xenograft studies. Methods: This open-label, dose-escalation (3+3 design) study evaluated the safety, tolerability and PK of AZD7762 (6–40 mg iv) alone and combined with gem (750 or 1000 mg/m2 iv) (NCT00413686). Pts received AZD7762 alone on days 1 and 8 (Cycle 0) followed by 7 days’ observation, then AZD7762 + gem on days 1 and 8...